Purpose: To evaluate the clinical outcome of an intravitreal injection of triamcinolone acetonide as treatment of diffuse diabetic macular edema.
Materials and methods: The prospective, interventional, clinical case series study included 20 patients (26 eyes) who received an intravitreal injection of 20 mg to 25 mg of triamcinolone acetonide as treatment of diffuse diabetic macular edema. The injection was done under topical anesthesia and sterile conditions in the operating room. Mean follow-up ranged at 6.64 ± 6.10 months. The study group was compared with a control group of 16 patients who underwent macular grid laser coagulations.
Results: In the study group, visual acuity increased significantly (p< 0.001) from 0.12 ± 0.08 at baseline to a maximum of 0.19 ± 0.14 during the follow-up. Seventeen (81%) of 21 eyes with a follow-up of more than 1 month gained in visual acuity. In the control group, visual acuity did not change significantly. In the study group, intraocular pressure increased significantly (p< 0.001) from 16.9 ± 2.5 mm Hg to a mean maximal value of 21.3 ± 4.7 mm Hg, and decreased significantly (p = 0.028) to 17.7 ± 4.7 mm Hg at the end of the study. This occurred parallel to the disappearance of the crystals in the vitreous. Intraocular pressure could be controlled with topical antiglaucomatous drops.
Conclusion: Intravitreal injection of 20 mg to 25 mg triamcinolone acetonide might increase visual acuity in patients with clinically significant diffuse diabetic macular edema.
Early Treatment Diabetic Retinopathy Study research group (1985) Photocoagulation for diabetic macular edema. Early Diabetic Retinopathy Study report number 1. Arch Ophthalmol 103: 1796–806CrossRefGoogle Scholar
Hida T, Chandler D, Arena JE, Machemer R (1986) Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Am J Ophthalmol 101: 190–5PubMedGoogle Scholar
McCuen BW, Bessler M, Tano Y, et al (1981) The lack of toxicity of intravitreally administered triamcinolone acetonide. Am J Ophthalmol 91: 785–8PubMedGoogle Scholar
Jonas JB, Hayler JK, Panda-Jonas S (2000) Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol 84: 1064–7PubMedCrossRefGoogle Scholar
Jonas JB, Hayler JK, Söfker A, Panda-Jonas S (2001) Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 131: 468–71PubMedCrossRefGoogle Scholar
Jonas JB, Kreissig I, Söfker A, Degenring R (2003) Intravitreal injection of triamcinolone for diffuse diabetic edema. Arch Ophthalmol 121: 57–61PubMedCrossRefGoogle Scholar
Jonas JB, Kreissig I, Degenring R (2003) Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol 87: 24–7PubMedCrossRefGoogle Scholar
Kreissig I, Degenring R, Jonas JB (2002) Intravitreal triamcinolone acetonide as treatment of central retinal vein occlusion. Ophthalmic Research 34: 162Google Scholar
Jonas JB, Kreissig I, Hugger P, Sander G, Panda-Jonas S, Degenring R (2003) Intravitreal triamcinolone acetonide for exudative age related macular degeneration. Br J Ophthalmol 87: 462–8PubMedCrossRefGoogle Scholar
Challa JK, Gillies MC, Penfold PL, et al (1998) Exudative macular degeneration and intravitreal triamcinolone: 18 months follow-up. Aust N Z J Ophthalmol 26: 277–81PubMedCrossRefGoogle Scholar
Jonas JB, Kreissig I, Degenring R (2002) Repeated intravitreal injections of triamcinolone acetonide as treatment of progressive exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 240: 872–3CrossRefGoogle Scholar